INM
Inmed Pharmaceuticals Inc
NASDAQ · Pharmaceuticals
$0.94
-0.04 (-4.21%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 849.9K | 790.8K | 761.6K |
| Net Income | 151.2K | 172.0K | 136.0K |
| EPS | — | — | — |
| Profit Margin | 17.8% | 21.8% | 17.9% |
| Rev Growth | +21.7% | +11.4% | +19.5% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 126.0K | 119.3K | 118.2K |
| Total Equity | 1.31M | 1.24M | 1.28M |
| D/E Ratio | 0.10 | 0.10 | 0.09 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 223.3K | 218.3K | 221.4K |
| Free Cash Flow | 102.9K | 109.5K | 116.5K |